<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00368420</url>
  </required_header>
  <id_info>
    <org_study_id>AGO-OVAR OP.2</org_study_id>
    <secondary_id>AGO DESKTOP OVAR II</secondary_id>
    <nct_id>NCT00368420</nct_id>
  </id_info>
  <brief_title>Validation of a Score of Predictive Factors for Complete Resection in Platinum-sensitive Recurrent Ovarian Cancer</brief_title>
  <official_title>Validation of a Score of Predictive Factors for Complete Resection in Platinum-sensitive Recurrent Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AGO Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Arbeitsgemeinschaft Gynaekologische Onkologie Austria</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>MITO</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AGO Study Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to validate a score developed by the AGO-OVAR for complete
      resection of the tumor
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The multicentre retrospective study AGO-DESKTOP OVAR 1 investigated in a multicentre-setting
      the question of prognostic factors for a successful (i.e. complete) debulking for recurrence.
      That way, a hypothesis for a score with 3 factors could be developed:

        -  PS ECOG = 0

        -  tumor-free after primary surgery (if unknown: FIGO I/II)

        -  Ascites &lt; 500 ml.

      The goal of this study is to evaluate in a prospective multicentre setting, to what extent
      this retrospectively defined AGO-score has predictive validity. The criterion aimed at is
      therefore the rate of complete tumor resections if the three score characteristics are
      present in invasive epithelial platinum-sensitive ovarian-, fallopian tube- or primary
      peritoneal cancer. This study will be the second in a series of three: (1) hypothesis
      building for a potential predictive score for resectability, (2) prospective confirmation of
      the AGO-score, and (3) application of the AGO-score as inclusion criteria for eligible
      patients in whom a formal comparison of the role of secondary debulking of relapsed ovarian
      cancer could be performed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">122</enrollment>
  <condition>Ovarian Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with recurrence of invasive epithelial ovarian-, fallopian tube- or primary
        peritoneal cancer of any initial stage who have relapsed after a tumor-free interval of at
        least 6 months after completion of first-line therapy.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with recurrence of invasive epithelial ovarian-, fallopian tube- or primary
             peritoneal cancer of any initial stage who have relapsed after a tumor-free interval
             of at least 6 months after completion of first-line therapy. The same interval applies
             to patients with second relapse who are enrolled after completed platinum-containing
             re-induction therapy.

          -  Women aged &gt; 18 years

          -  Patients who have given their signed and written informed consent to data transmission
             and -processing

        Exclusion Criteria:

          -  Patients with non-epithelial tumors as well as borderline tumors

          -  Patients who undergo second-look surgery or completion surgery after end of
             chemotherapy or during the interval

          -  Only for the study collective: patients with second malignancies who have been treated
             by laparotomy, as well as other neoplasias, if the treatment could interfere with the
             treatment of relapsed ovarian cancer

          -  Patients with a third recurrence

          -  Patients with so-called platinum-refractory tumor, i.e. progression during
             chemotherapy or recurrence within 6 months after end of former platinum-containing
             therapy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philipp Harter, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dr. Horst Schmidt Klinik Wiesbaden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Annette Hasenburg, PD Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Universitäts-Frauenklinik Freiburg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andreas du Bois, Prof. Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Dr. Horst Schmidt Klinik Wiesbaden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätskliniken LKH Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Johann Wolfgang Goethe Universität</name>
      <address>
        <city>Frankfurt</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincentius Kliniken gAG</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76135</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Landshut gGmbH</name>
      <address>
        <city>Landshut</city>
        <zip>84034</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städtisches Krankenhaus Lüneburg</name>
      <address>
        <city>Lüneburg</city>
        <zip>21339</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Neumarkt</name>
      <address>
        <city>Neumarkt</city>
        <zip>92318</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HSK, Dr. Horst Schmidt Klinik</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Stadt Wolfsburg</name>
      <address>
        <city>Wolfsburg</city>
        <zip>38440</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catholic University of Sacred Heart</name>
      <address>
        <city>Campobasso</city>
        <zip>86100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>European Institute of Oncology</name>
      <address>
        <city>Milan</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Harter P, Sehouli J, Reuss A, Hasenburg A, Scambia G, Cibula D, Mahner S, Vergote I, Reinthaller A, Burges A, Hanker L, Pölcher M, Kurzeder C, Canzler U, Petry KU, Obermair A, Petru E, Schmalfeldt B, Lorusso D, du Bois A. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer. 2011 Feb;21(2):289-95. doi: 10.1097/IGC.0b013e31820aaafd.</citation>
    <PMID>21270612</PMID>
  </results_reference>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2006</study_first_submitted>
  <study_first_submitted_qc>August 23, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2006</study_first_posted>
  <last_update_submitted>February 11, 2011</last_update_submitted>
  <last_update_submitted_qc>February 11, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2011</last_update_posted>
  <keyword>ovarian cancer</keyword>
  <keyword>recurrence</keyword>
  <keyword>surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

